EGFR or PD-L1 decision for first line therapy in a case series of EGFR positive and PD-L1 >50.
| Title | EGFR or PD-L1 decision for first line therapy in a case series of EGFR positive and PD-L1 >50. |
| Publication Type | Journal Article |
| Year of Publication | 2017 |
| Authors | Zarogoulidis, P., Chinelis P., Efthymiou C., Athanasiadou A., Mpikos V., Papatsibas G., Papadopoulos V., Maragouli E., Huang H., Trakada G., Kallianos A., Veletza L., & Hohenforst-Schmidt W. |
| Journal | Respir Med Case Rep |
| Volume | 22 |
| Pagination | 7-10 |
| Date Published | 2017 |
| ISSN | 2213-0071 |
| Abstract | Targeted therapies are on the market for the past five years and recently pembrolizumab was approved as first line treatment for patients with PD-L1 >50%. We present three cases of patients which had epidermal growth factor receptor positive expression and programmed death-ligand 1 (PD-L1), PD-L1 >50% overexpression. |
| DOI | 10.1016/j.rmcr.2017.05.010 |
| Alternate Journal | Respir Med Case Rep |
| PubMed ID | 28761805 |
| PubMed Central ID | PMC5524632 |
